ExodusPoint Capital Management LP Buys 33,086 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ExodusPoint Capital Management LP increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 183,395 shares of the medical equipment provider’s stock after purchasing an additional 33,086 shares during the quarter. ExodusPoint Capital Management LP owned about 0.09% of Zimmer Biomet worth $19,372,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Cinctive Capital Management LP acquired a new stake in Zimmer Biomet in the fourth quarter worth about $4,412,000. Huntington National Bank boosted its stake in shares of Zimmer Biomet by 17.2% in the 4th quarter. Huntington National Bank now owns 7,013 shares of the medical equipment provider’s stock valued at $741,000 after purchasing an additional 1,027 shares during the last quarter. Groupama Asset Managment acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $762,000. Diametric Capital LP bought a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $381,000. Finally, National Bank of Canada FI lifted its holdings in Zimmer Biomet by 27.5% in the fourth quarter. National Bank of Canada FI now owns 263,462 shares of the medical equipment provider’s stock valued at $27,830,000 after buying an additional 56,797 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. JMP Securities restated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Up 0.2 %

Shares of NYSE:ZBH opened at $112.72 on Friday. The company’s 50-day moving average price is $107.38 and its two-hundred day moving average price is $107.21. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $130.89. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $22.44 billion, a PE ratio of 25.33, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.